Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Metastasis02:30

Metastasis

5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Tumor Immunotherapy01:27

Tumor Immunotherapy

556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

14
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
14
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial.

Circulation. Cardiovascular interventions·2026
Same author

Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Thrombosis and haemostasis·2025
Same author

Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.

Journal of the American Heart Association·2025
Same author

Triangulating data to define patient pathways, diagnostic and treatment patterns, and outcomes in cancer patients with deep vein thrombosis in Germany: a mixed-methods real-world data study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Dual pathway inhibition in patients with peripheral artery disease in Germany.

VASA. Zeitschrift fur Gefasskrankheiten·2025
Same author

Danaparoid-Consensus Recommendations on Its Clinical Use.

Pharmaceuticals (Basel, Switzerland)·2025
Same journal

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
查看所有相关文章

相关实验视频

Updated: Jul 18, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

[与瘤相关的血栓形成]

Rupert Bauersachs1

  • 1GefäßCentrum, CCB - Cardioangiologisches Centrum Bethanien, Frankfurt am Main, Germany.

Deutsche medizinische Wochenschrift (1946)
|August 23, 2023
PubMed
概括
此摘要是机器生成的。

直接的FXa抑制剂为癌症相关的血栓形成 (CAT) 提供了比传统的低分子量肝素 (LMWH) 更安全,更有效的抗凝治疗方法. 口服疗法需要谨慎使用,特别是在某些瘤中,但剂量降低可能适合特定患者.

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.1K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.4K

相关实验视频

Last Updated: Jul 18, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.1K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.4K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 血液学 血液学 血液学
  • 在瘤学瘤学.

背景情况:

  • 低分子量肝素 (LMWH) 已成为癌症相关血栓瘤 (CAT) 治疗的标准.
  • 有证据表明,LMWH会增加出血的风险.
  • 直接XA因子 (FXa) 抑制剂是一种潜在的替代疗法.

研究的目的:

  • 为了比较直接的FXa抑制剂的安全性和有效性与CAT的LMWH.
  • 评估与癌症患者口服抗凝剂相关的风险.
  • 探索其他抗凝策略,如剂量降低.

主要方法:

  • 随机对照试验 (RCT) 的综述,比较直接的FXa抑制剂和LMWH.
  • 分析与不同抗凝血方法相关的出血风险.
  • 在患有胃肠道或尿路瘤的患者中评估口服治疗的风险.
  • 在稳定的患者中考虑降低二次预防剂量.

主要成果:

  • 直接的FXa抑制剂在许多CAT患者中显示出比LMWH更好的安全性和潜在的疗效.
  • 口服抗凝药需要谨慎使用,特别是在局部胃肠道或尿道瘤的情况下.
  • 治疗LMWH与显著的出血风险有关.
  • 六个月后降低剂量可能是一个可行的,低风险的选择,选择稳定的患者,等待个人利益风险评估.

结论:

  • 与LMWH相比,直接的FXa抑制剂是CAT的首选,更安全,可能更有效的抗凝选择.
  • 仔细考虑口服治疗是至关重要的,特别是在特定的癌症患者亚组.
  • 个性化治疗决策,包括潜在的剂量降低,对于优化CAT管理中的抗凝血是必不可少的.